With large vaccine trials
planned and monoclonal antibody trials underway, efficacy data could come this
fall or winter
By Ryan Cross, Chemical and Engineering News
June 18, 2020 -- “Large trials this summer and fall could provide the first evidence that some of the experimental COVID-19 vaccines are working. AstraZeneca, which is developing an adenoviral vector vaccine designed at the University of Oxford, is recruiting 10,000 people in the UK, 30,000 people in the US, and potentially 2,000 people in Brazil for its Phase III study to determine if the vaccine is effective. If the trial is successful, AstraZeneca says, it could start distributing the vaccine as early as September in the UK and October in the US.”
Full article at: https://cen.acs.org/pharmaceuticals/drug-development/COVID-19-vaccines-antibodies-advance/98/i24
By Ryan Cross, Chemical and Engineering News
June 18, 2020 -- “Large trials this summer and fall could provide the first evidence that some of the experimental COVID-19 vaccines are working. AstraZeneca, which is developing an adenoviral vector vaccine designed at the University of Oxford, is recruiting 10,000 people in the UK, 30,000 people in the US, and potentially 2,000 people in Brazil for its Phase III study to determine if the vaccine is effective. If the trial is successful, AstraZeneca says, it could start distributing the vaccine as early as September in the UK and October in the US.”
Full article at: https://cen.acs.org/pharmaceuticals/drug-development/COVID-19-vaccines-antibodies-advance/98/i24
No comments:
Post a Comment